NanoViricides, Inc. :NNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : December 5, 2016

NanoViricides, Inc. reports financial results for the quarter ended September 30, 2016.


  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -3.06 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • NNVC-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were down this period to 21.91 million compared to 29.48 million in the same period last year.
  • With debt at a relatively low 10.54% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 12.08%), and relatively tight interest coverage level of -3.57x, NNVC-US would have a hard time raising much additional debt. Thus, the company is classified as having Limited Flexibility when it comes to raising more debt.
  • Of the 9 chosen peers for the company, only 7 of the stocks have an outstanding debt balance. Companies with no debt include CMRX-US and NBY-US.
  • Net income of -3.06 million this period compared to a net income of -1.65 million last period. This is a growth of -85.46% over the previous period. In comparison, the peer group grew at 4.64%

Access our Ratings and Scores for NanoViricides, Inc.

Earnings Growth YOY %
Cash & ST Investments %

Access our Ratings and Scores for NanoViricides, Inc.

Company Profile

NanoViricides, Inc. is a nano-biopharmaceutical company. The company engages in the discovery, development, and commercialization of therapeutics to advance the care of patients suffering from life-threatening viral infections. It intends to manufacture Injectable and Oral FluCide, HIVCide, Nanoviricide Eye Drops, HerpeCide, DengueCide, RabiCide as well as other drugs for pre-clinical animal studies and human clinical studies. NanoViricides was founded by Anil R. Diwan on July 25, 2000 and is headquartered in Shelton, CT.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of NNVC-US.